EFFECTS OF ALPHA-DIFLUOROMETHYLORNITHINE ALONE AND COMBINED WITH ADRIAMYCIN OR VINDESINE ON L1210 LEUKEMIA IN MICE, EMT6 SOLID TUMORS IN MICE, AND SOLID TUMORS INDUCED BY INJECTION OF HEPATOMA TISSUE-CULTURE CELLS IN RATS

  • 1 January 1981
    • journal article
    • research article
    • Vol. 41  (12) , 5158-5161
Abstract
The effects of .alpha.-difluoromethylornithine (DFMO; RMI 71782) in combination with vindesine or adriamycin were investigated in 3 different animal tumor models. When given in a concentration of 2% in drinking water to C57BL/6 .times. DBA/2 F1 mice inoculated i.p. with L1210 leukemia cells, DFMO prolonged the survival time 1.2-fold. Treatment with vindesine (0.1 mg/kg per wk i.p.) or adriamycin (2.5 mg/kg per wk i.p.) increased the mean survival time 1.4- and 2.3-fold, respectively. DFMO with vindesine doubled survival time, while DFMO with adriamycin increased it 3.5-fold and yielded 30% long-term survivors. The growth of solid tumors induced in Buffalo rats by i.m. injection of hepatoma tissue culture cells was inhibited 65% after 2 wk of DFMO treatment. Similar inhibition of growth could be achieved by weekly i.p. injections of vindesine (0.2 mg/kg) or adriamycin (2.5 mg/kg). When the same doses of these drugs were administered in combination with DFMO, the growth of this hepatoma was completely arrested. Combined treatment of BALB/c mice bearing s.c. solid EMT6 [mammary] tumors with DFMO and adriamycin or vindesine also resulted in enhanced inhibition of tumor growth compared to single-drug therapy. Combination of DFMO with vindesine or adriamycin is evidently an effective approach to the treatment of several animal cancers.

This publication has 10 references indexed in Scilit: